ABSTRACT
introduction: Despite many advances in both surgery and radiotherapy, the treatment of esophageal cancer remains a challenge for both surgeons and oncologists. The treatment of choice for patients with carcinoma esophagus is controversial. Recent studies have suggested that combined chemotherapy and radiation therapy may result in improved survival. Aim: The aim of our study was to analyze the role of concurrent chemoradiation in inoperable carcinomas esophagus. Materials and Methods: This single-arm prospective study was conducted in the Department of Radiotherapy, Thanjavur Medical College Hospital from August 2018 to August 2019 to analyze the role of concurrent chemoradiation in inoperable carcinomas esophagus. A total of 26 cases of inoperable cases of carcinoma esophagus were treated with once-weekly cisplatin 30 mg/ m2 along with radiotherapy 60 Gy in 30 fractions in 6 weeks on telecobalt machine. Results: Of 26 patients 16 patients were males, 10 patients were females, 17 patients had age <60 years, 9 patients had age above 61 years, 22 patients had squamous cell carcinoma, 4 patients had adenocarcinoma, 4 patients had lesion in upper part of esophagus, 14 patients had lesion in middle part, 8 patients had lesion in lower part, 4 patients had tumor dimension <5 cm, 22 patients had dimension >5.1 cm, 2 patients had tumor stage T1, 22 patients had T2, 2 patients had T3, 1 patient had Nx, 21 patients had No, 4 patients had N1, 15 patients had mild dysphagia, 8 patients had moderate dysphagia, 3 patients had severe dysphagia1 patients had diarrhea, 1 patient had fatigue, 4 patients had leukopenia, and 1 patient had neutropenia. Conclusion: Combined modality therapy plays a significant role in the treatment of patients with carcinoma esophagus. Concurrent chemoradiation is a superior treatment in inoperable carcinoma esophagus in terms of local control and survival. Hence, concurrent chemoradiation can also be tried in early cases and surgical morbidity survival and quality of life can be improved.
ABSTRACT
Introduction: About 30% of all colorectal tumors develop in the rectum. The location of the rectum within the bony pelvisand its proximity to vital structures presents significant therapeutic challenges when considering neoadjuvant options andsurgical interventions. Neoadjuvant therapy may comprise either radiotherapy (RT) alone or in combination with chemotherapy.Commonly prescribed chemotherapy agents include 5-fluorouracil and oxaliplatin. These agents act to limit tumor cell divisionin several ways.Aim: The aim of this study was to study the outcome of patients with locally advanced rectal cancer treated with neoadjuvantchemotherapy and RT.Materials and Methods: Patients with locally advanced pathologically confirmed adenocarcinoma of the rectum, without detectabledistant metastasis at presentation, were included in this study. Patients underwent neoadjuvant chemotherapy and radiation therapy.Results: In 67 patients, 63% of patients were female; Stage IIA cases were 69% followed by Stages IIB and IIC 10% in each.About 19% of patients underwent surgery and 81% of patients underwent neoadjuvant chemoradiation followed by reassessmentfor surgery. Overall survival in 3 years in this study was noted as 67.6%.Conclusion: Neoadjuvant chemoradiation followed by radical surgery has shown very satisfactory results in the managementof locally advanced rectal cancers.
ABSTRACT
Aim: The aim of this study is to assess the efficacy, toxicity, and feasibility of hypofractionated radiotherapy in post-mastectomybreast cancer patients compared with conventional radiotherapy.Materials and Methods: A total of 80 post-mastectomy breast cancer patients were randomized into two groups for adjuvantradiotherapy. Control group of 40 patients received conventional radiotherapy of 50 GY in 5 weeks. Study group of 40 patientsreceived hypofractionated radiotherapy of 42.72 GY in 3.1 weeks.Results: The statistical analysis of the study was performed in terms of tolerability, radiation toxicities, and feasibility of thehypofractionated radiotherapy over conventional radiotherapy. There was found to be no significant difference between thetwo groups.Conclusion: In breast cancer patients after post-mastectomy, hypofractionated radiotherapy in comparison to conventionalradiotherapy finds comparable outcomes without any significant difference in radiation-induced toxicities.